Mergers & acquisitions
Pfizer’s consumer health business has been spurned again. This time by mega-consumer goods company Proctor & Gamble. which opted today to acquire Germany-based Merck KGaA’s consumer health unit for $4.2 billion.
Takeda Pharmaceutical has made an official bid to acquire London’s Shire for about $60 billion. And in breaking news, Shire rejected the bid, saying it undervalued the company.
Sanofi has agreed to sell its generics division, Zentiva, to Advent International. The deal is expected to wrap by the end of this year.
Only a couple weeks after Takeda Pharmaceuticals announced it was interested in buying Shire, Shire sells its oncology business to France’s Servier for $2.4 billion.
There has been speculation for several years whether Pfizer Inc. would consider buying Bristol-Myers Squibb. That appears to have been laid to rest by comments made by Pfizer’s chief executive officer, Ian Read.
The people at Eloxx Pharmaceuticals share a common goal — to bring safe and effective therapies to children and adults suffering from rare genetic diseases as quickly as possible.
Alexion Pharmaceuticals is buying Wilson Therapeutics for $855 million. With the company, Alexion will acquire WTX101, Wilson Therapeutics’ Phase III compound for Wilson disease.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Swiss pharma giant Roche has had an active April so far. The company has acquired a multiple sclerosis program, completed the acquisition of a company and secured a big win with the United Kingdom’s healthcare provider for lung cancer drug Tecentriq.
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
PRESS RELEASES